Evidence map›Paper›PMID 26202968›Full record

ArticleNucleic acids research2015

Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD.

Mitsunori Koga, Megumi Hayashi, Daisuke Kaida

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. International journal of molecular sciences · 2021
    Article
  13. Rbm38 Reduces the Transcription Elongation Defect of theInternational journal of molecular sciences · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mitsunori KogaFrontier Research Core for Life Sciences, University of Toyama, Toyama 930-0194, Japan.
Megumi HayashiFrontier Research Core for Life Sciences, University of Toyama, Toyama 930-0194, Japan.
Daisuke KaidaFrontier Research Core for Life Sciences, University of Toyama, Toyama 930-0194, Japan kaida@med.u-toyama.ac.jp.
University of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphorylation of the C-terminal domain of the largest subunit of RNA polymerase II (Pol II), especially Ser2 and Ser5 residues, plays important roles in transcription and mRNA processing, including 5' end capping, splicing and 3' end processing. These phosphorylation events stimulate mRNA processing, however, it is not clear whether splicing activity affects the phosphorylation status of Pol II. In this study, we found that splicing inhibition by potent splicing inhibitors spliceostatin A (SSA) and pladienolide B or by antisense oligos against snRNAs decreased phospho-Ser2 level, but had little or no effects on phospho-Ser5 level. In contrast, transcription and translation inhibitors did not decrease phospho-Ser2 level, therefore inhibition of not all the gene expression processes cause the decrease of phospho-Ser2. SSA treatment caused early dissociation of Pol II and decrease in phospho-Ser2 level of chromatin-bound Pol II, suggesting that splicing inhibition causes downregulation of phospho-Ser2 through at least these two mechanisms.

Indexed as

RNA SplicingChromatinDown-RegulationHeLa CellsHumansOligonucleotides, AntisensePhosphorylationPositive Transcriptional Elongation Factor BProtein Structure, TertiaryPyransRNA Polymerase IIRNA, Small NuclearSerineSpiro CompoundsChromatinOligonucleotides, AntisensePositive Transcriptional Elongation Factor BPyransRNA Polymerase IIRNA, Small NuclearSerineSpiro Compoundsspliceostatin A

Identifiers

PMID26202968
PMCPMC4787822
OpenAlexW2124690990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.